Merck KGaA's EBIT is $3.4B, below the sector sector average of $2.3T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest EBIT for MKKGY is $3.4B as of September 2026. That compares with $4.1B in the prior-year period — down 17.2% year over year. That is below the sector sector average of $2.3T. Investors often review this figure alongside Merck KGaA's historical trend and sector peers before judging valuation or financial health.
Over the past year, MKKGY's EBIT moved from $4.1B to $3.4B — a 17.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Merck KGaA's operating scale or balance-sheet position.
Against its sector companies, MKKGY currently prints $3.4B for EBIT, while the sector average sits near $2.3T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Merck KGaA's growth, margins, and balance sheet.
A EBIT figure of $3.4B for MKKGY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.3T. Explore the charts below for those layers of context.
After noting MKKGY's EBIT ($3.4B), review year-over-year change from $4.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.